靶向干细胞及异型增生特征:双重抑制MEK/ERK与STAT3在胃癌发生中的作用
研究利用Mist1-Kras小鼠及20例人胃癌前病变类器官,发现吡维铵在化生类器官中引起生长停滞、在异型增生类器官中诱导细胞死亡,并下调ERK与STAT3磷酸化;单细胞测序显示其靶向CD133+/CD166+干细胞群及增殖细胞;体内实验显示吡维铵抑制化生进展并促进正常泌酸腺恢复。
要点
- 吡维铵在化生类器官中导致生长停滞,在异型增生类器官中诱导细胞死亡。
- 吡维铵显著下调ERK和STAT3磷酸化及STAT3靶基因。
- 吡维铵靶向CD133+/CD166+干细胞群及异型增生类器官中的增殖细胞。
核心结论
- 吡维铵通过双重阻断MEK/ERK和STAT3信号通路,有效诱导化生组织生长停滞和异型增生细胞死亡。
- 作者认为吡维铵是一种有前景的化疗药物,可重编程癌前环境以预防胃癌发生。
研究设计与样本
- 研究使用源自Mist1-Kras小鼠的化生和异型增生类器官,以及从胃癌患者建立的20例人癌前病变类器官系。
- 进行磷酸化抗体阵列分析和单细胞RNA测序以识别吡维铵影响的靶细胞群和信号通路。
- 将吡维铵给予Mist1-Kras小鼠以评估体内药物有效性。
主要发现
- 吡维铵处理导致化生类器官生长停滞,而在异型增生类器官中诱导细胞死亡。
- 吡维铵处理显著下调ERK和信号转导及转录激活因子3(STAT3)的磷酸化以及STAT3靶基因。
- 单细胞RNA测序数据分析显示,吡维铵特异性靶向CD133+/CD166+干细胞群以及异型增生类器官中的增殖细胞。
- 吡维铵抑制Mist1-Kras小鼠的化生进展并促进正常泌酸腺的恢复。
- 吡维铵通过同时阻断MEK/ERK和STAT3信号通路,对具有异型增生特征的人类器官生长和存活表现出抑制作用。
关键数值与推荐
- 在Mist1-Kras小鼠化生类器官中,吡维铵导致生长停滞;在异型增生类器官中诱导细胞死亡。
- 吡维铵显著下调ERK和STAT3磷酸化及STAT3靶基因。
- 单细胞RNA测序显示吡维铵靶向CD133+/CD166+干细胞群和增殖细胞。
- 在Mist1-Kras小鼠中,吡维铵抑制化生进展并促进正常泌酸腺恢复。
- 在人异型增生特征类器官中,吡维铵通过同时阻断MEK/ERK和STAT3通路抑制生长和存活。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS & AIMS: Precancerous metaplasia progression to dysplasia can increase the risk of gastric cancers. However, effective strategies to specifically target these precancerous lesions are currently lacking. To address this, we aimed to identify key signaling pathways that are upregulated during metaplasia progression and critical for stem cell survival and function in dysplasia. METHODS: To assess the response to chemotherapeutic drugs, we used metaplastic and dysplastic organoids derived from Mist1-Kras mice and 20 human precancerous organoid lines established from patients with gastric cancer. Phospho-antibody array analysis and single-cell RNA-sequencing were performed to identify target cell populations and signaling pathways affected by pyrvinium, a putative anticancer drug. Pyrvinium was administered to Mist1-Kras mice to evaluate drug effectiveness in vivo. RESULTS: Although pyrvinium treatment resulted in growth arrest in metaplastic organoids, it induced cell death in dysplastic organoids. Pyrvinium treatment significantly downregulated phosphorylation of ERK and signal transducer and activator of transcription 3 (STAT3) as well as STAT3-target genes. Single-cell RNA-sequencing data analyses revealed that pyrvinium specifically targeted CD133+/CD166+ stem cell populations, as well as proliferating cells in dysplastic organoids. Pyrvinium inhibited metaplasia progression and facilitated the restoration of normal oxyntic glands in Mist1-Kras mice. Furthermore, pyrvinium exhibited suppressive effects on the growth and survival of human organoids with dysplastic features, through simultaneous blocking of the MEK/ERK and STAT3 signaling pathways. CONCLUSIONS: Through its dual blockade of MEK/ERK and STAT3 signaling pathways, pyrvinium can effectively induce growth arrest in metaplasia and cell death in dysplasia. Therefore, our findings suggest that pyrvinium is a promising chemotherapeutic agent for reprogramming the precancerous milieu to prevent gastric cancer development.
引用
- Kim H, Jang B, Zhang C, et al. Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis. Gastroenterology. 2023. PMID: 37802423. doi:10.1053/j.gastro.2023.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。